Hagiwara Satoru, Kudo Masatoshi, Kawasaki Toshihiko, Nagashima Miki, Minami Yasunori, Chung Hobyung, Fukunaga Toyokazu, Kitano Masayuki, Nakatani Tatsuya
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan.
J Gastroenterol. 2006 Dec;41(12):1214-9. doi: 10.1007/s00535-006-1950-7. Epub 2007 Feb 6.
Factors involved in portal venous invasion (PVI) must be clarified to enable better determination of therapeutic strategies and outcomes in patients with hepatocellular carcinoma (HCC).
Of 365 patients with HCC who consulted our department between January 1999 and January 2003, 53 with PVI at the initial consultation were excluded, and the other 312 without PVI were included in this study. Of these patients, we compared liver function, tumor markers, and initial treatment between 287 patients without PVI during follow-up (until December 2004) and 25 patients who developed PVI, and investigated prognostic factors.
Multivariate analysis using a COX regression model showed that a Lens culinaris A-reactive fraction of alpha-fetoprotein (AFP-L3) rate of 15% or more, a des-gamma-carboxy prothrombin (DCP) level of 100 mAU/ml or more, multiple tumors, and a platelet count of 130 000/mm(3) or more were correlated with PVI.
HCC frequently infiltrated the portal vein in patients with a high rate of AFP-L3, a high level of DCP, or multiple tumors. Furthermore, the incidence of PVI was significantly higher in patients with a platelet count of 130 000/mm(3) or more.
必须明确门静脉侵犯(PVI)所涉及的因素,以便更好地确定肝细胞癌(HCC)患者的治疗策略和预后。
在1999年1月至2003年1月间到我院就诊的365例HCC患者中,排除初诊时即有PVI的53例,将其余312例无PVI的患者纳入本研究。在这些患者中,我们比较了随访期间(至2004年12月)无PVI的287例患者和发生PVI的25例患者的肝功能、肿瘤标志物及初始治疗情况,并研究了预后因素。
使用COX回归模型进行多因素分析显示,甲胎蛋白(AFP)的豆凝集素A反应性组分(AFP-L3)率≥15%、异常凝血酶原(DCP)水平≥100 mAU/ml、多肿瘤以及血小板计数≥130 000/mm³与PVI相关。
AFP-L3率高、DCP水平高或多肿瘤的HCC患者常侵犯门静脉。此外,血小板计数≥130 000/mm³的患者PVI发生率显著更高。